Workflow
TOUYUN BIOTECH(01332)
icon
Search documents
智通港股52周新高、新低统计|5月30日
智通财经网· 2025-05-30 08:44
52周新低排行 | 股票名称 | 收盘价 | 最低价 | | 创低率 | | --- | --- | --- | --- | --- | | 声通科技(02495) | 113.800 | 101.900 | -15.79% | | | 百德国际(02668) | 0.163 | 0.155 | -10.92% | | | INTL GENIUS(00033) | 0.700 | 0.700 | -5.41% | | | 中国铸晨81(00810) | 0.126 | 0.126 | -4.55% | | | 派格生物医药-B | 10.200 | 10.000 | -4.21% | | --- | --- | --- | --- | | (02565) | | | | | 中国前沿科技集团 | 0.580 | 0.570 | -3.39% | | (01661) | | | | | 吉宏股份(02603) | 9.710 | 9.630 | -3.31% | | 透云生物(01332) | 0.084 | 0.083 | -2.35% | | 超智能控股(01402) | 0.170 | 0.166 | - ...
整理:每日港股市场要闻速递(5月7日 周三)
news flash· 2025-05-07 01:13
4. 透云生物(01332.HK):附属拟1300万元出售威道国际70%股权。 5. 歌礼制药(01672.HK):将在第32届欧洲肥胖症大会(ECO 2025)上以口头和壁报形式报告脂肪靶向、减 重不减肌的肥胖症候选药物ASC47的早期研究。 金十数据整理:每日港股市场要闻速递(5月7日 周三) 1. 正荣地产(06158.HK):控股股东委任联合清盘人,股份自周三上午9时起恢复买卖。业务运作一切如 常。 2. 小鹏汽车(09868.HK)拟5月21日举行董事会会议批准一季度业绩。 3. 协合新能源(00182.HK):前4个月权益发电量为3330.69GWh,同比跌2.24%;4月权益发电量为 809.84GWh,同比跌6.48%。 6. 远大医药(00512.HK):全球创新产品 STC3141 在中国开展的用于治疗脓毒症的 II 期临床研究成功达 到临床终点。 7. 山高新能源(01250.HK):前2个月累计总营运发电量约101.96万兆瓦时,同比增长约13.1%。 ...
透云生物(01332) - 2024 - 年度财报
2025-04-29 10:19
Financial Performance - For the fiscal year ending December 31, 2024, the company recorded revenue of approximately HKD 160 million, a decrease of about 19.4% compared to HKD 198.6 million in 2023[9]. - The loss for the fiscal year was approximately HKD 88 million, a significant reduction of about 67.7% from HKD 272.6 million in 2023[9]. - The decrease in loss was primarily due to a reduction in fair value losses on financial assets and a decrease in impairment of property, plant, and equipment[9]. - The QR code business generated revenue of approximately HKD 60.4 million, down about 14.7% from HKD 70.8 million in 2023, with a segment loss of approximately HKD 9.5 million[18]. - The packaging products business recorded revenue of approximately HKD 75.8 million for the year ended December 31, 2024, a decrease of about 29.1% compared to HKD 106.9 million in 2023, with a segment loss of approximately HKD 7.4 million[19]. - The Rhyne algae product business generated revenue of approximately HKD 16.1 million, a decrease from HKD 20.3 million in 2023, with a segment loss of approximately HKD 13 million, significantly reduced from HKD 106.1 million in the previous year[22]. - As of December 31, 2024, the company held outstanding unsecured borrowings of approximately HKD 297.4 million and secured bank borrowings of approximately HKD 68.7 million, with an asset-liability ratio of about 113%, up from 94% in 2023[25]. - The total employee cost for the year, including director remuneration, was approximately HKD 69,000,000, a decrease from HKD 70,400,000 in 2023[79]. Business Strategy and Development - The company plans to expand its product offerings, including low glycemic index foods and new applications for its products, such as plant-based fish and shrimp[12]. - The company has entered over 2,000 retail and food service locations in the Chinese market, establishing a solid foundation for business growth in 2024[12]. - The company aims to enhance product and process research and development to improve production efficiency and reduce energy consumption[10]. - The company is focusing on developing two product lines and enhancing market exposure through various sales channels and marketing activities[10]. - The company anticipates launching various new products using green and white strains of its algae by 2025 to meet diverse customer needs[13]. - The company has a strategic focus on expanding its QR code business and enhancing its technological capabilities through research and development investments[38]. Investments and Financial Management - The financial investment business reported a fair value gain of approximately HKD 4.6 million, compared to a fair value loss of approximately HKD 0.9 million in the previous year, while the fair value loss for non-trading financial assets was approximately HKD 38.1 million, down from HKD 99.5 million in 2023[20]. - As of December 31, 2024, the group held significant investments valued at approximately HKD 51.2 million in listed investments and HKD 95.9 million in unlisted investments[43]. - The fair value of the group's significant investments accounted for 5% or more of total assets, with specific investments including HKD 37,168,000 in Haotian International Construction Investment Group[43]. - The company has a strong network in capital markets in Hong Kong and China, enhancing its investment and acquisition capabilities[49]. - The company has been involved in various sectors, including mining, logistics, education, and internet industries, showcasing its diverse investment portfolio[49]. Corporate Governance - The independent auditor, Deloitte Touche Tohmatsu, has audited the financial statements and is eligible for reappointment[94]. - The board of directors will consider various factors, including financial performance and economic conditions, before recommending any dividend payments[68]. - The board has established three committees: audit committee, remuneration committee, and nomination committee, to assist in governance[108]. - The company emphasizes the importance of corporate governance for sustainable growth and stakeholder value creation[99]. - The board has not established a corporate governance committee, with responsibilities shared among all board members[123]. Environmental, Social, and Governance (ESG) Initiatives - The company has implemented an environmental policy aimed at reducing its environmental impact and promoting employee health and safety[145]. - The group has implemented a "zero wastewater discharge" goal by achieving 100% reuse of production wastewater in its Shanxi algae business[168]. - The group plans to continue enhancing its ESG governance framework and align with national "dual carbon" strategies for sustainable development[168]. - The average customer satisfaction rate reached 97% with no product recalls due to safety and health reasons during the year[173]. - The company aims to reduce its carbon footprint by enhancing energy efficiency and reducing emissions through various measures[175]. Risk Management - The company is actively monitoring currency risks, particularly with revenues primarily denominated in USD and RMB, and expenses in HKD and RMB[32]. - The board acknowledges the importance of the internal control system for risk management and compliance with laws and regulations[141]. - The company has identified acute risks from extreme weather events, which could lead to revenue loss and increased operational costs[182]. - Chronic risks such as rising average temperatures may increase operational costs related to cooling systems and health protection measures[182]. - The company regularly assesses climate-related risks and develops targeted strategies to mitigate potential negative impacts on financial performance[186].
透云生物建议採纳新购股权计划及终止现有购股权计划
Zhi Tong Cai Jing· 2025-04-24 13:36
上市规则第17章的修订已自2023年1月1日起生效。为此,公司建议终止现有购股权计划并採纳新购股权 计划,该计划将自新购股权计划採纳之日起为期十年有效。新购股权计划的条文将符合2023年1月1日起 生效的经修订上市规则第17章的规定。 董事相信,新购股权计划将有助本集团吸引及挽留本集团的优秀人才,为合资格参与者提供额外激励, 并促进本集团业务的整体成功。此外,新购股权计划将向合资格参与者提供一个于公司拥有个人权益的 机会,有助于激励合资格参与者提高其表现及效率,并吸引及挽留对本集团长远增长及盈利能力有重要 贡献的合资格参与者。 透云生物(01332)发布公告,于2025年4月24日,董事会通过决议,建议採纳新购股权计划及终止现有购 股权计划,以供股东于股东周年大会上批准。 现有购股权计划乃于2022年6月2日获公司採纳,有效期为採纳日期起计十年。根据现有购股权计划的条 款,公司可随时于股东大会上通过决议案终止现有购股权计划,在此情况下不得进一步授出购股权,惟 购股权计划的条文将继续有效,以使在终止前已授出或可能根据现有购股权计划条文须予行使的任何购 股权可继续行使。在终止前根据现有购股权计划授出的购股权应继续 ...
透云生物(01332) - 2024 - 年度业绩
2025-03-26 13:17
Financial Performance - For the fiscal year ending December 31, 2024, the company reported a net loss of HKD 88,040,000, compared to a net loss of HKD 272,569,000 in the previous year, representing a 67.7% improvement[3]. - The company’s total comprehensive loss for the year was HKD 87,499,000, compared to HKD 271,023,000 in the previous year, indicating a significant reduction of 67.7%[4]. - The basic and diluted loss per share improved to HKD 0.10 in 2024 from HKD 0.314 in 2023, reflecting a decrease in loss per share of 68.3%[3]. - The company reported a net interest income of HKD 1,598,000, compared to a net loss of HKD 2,729,000 in the previous year, indicating a positive shift in financial performance[3]. - Other income, gains, and losses for 2024 amounted to a net loss of HKD 30,532,000, compared to a net loss of HKD 174,834,000 in 2023, indicating a significant improvement[24]. Revenue and Sales - Total revenue from sales of goods and services for 2024 was HKD 152,299,000, down from HKD 198,032,000 in 2023, indicating a decrease of 23.1%[3]. - The revenue from the packaging products business in 2024 is HKD 75,847,000, down 29.0% from HKD 106,909,000 in 2023[17]. - The revenue from the QR code business was approximately HKD 60,400,000, a decrease of about 14.7% from HKD 70,800,000 in 2023, with a segment loss of approximately HKD 9,500,000[75]. - The algae product business generated revenue of HKD 16,085,000 in 2024, a decline of 20.0% from HKD 20,323,000 in 2023[17]. - The total revenue from all segments combined was HKD 152,299,000 in 2024, down from HKD 198,032,000 in 2023, reflecting an overall decrease of approximately 23.1%[23]. Expenses and Cost Management - Administrative expenses decreased to HKD 100,453,000 in 2024 from HKD 118,007,000 in 2023, a reduction of 14.9%[3]. - Research and development expenses for 2024 are HKD 20,918,000, down from HKD 22,293,000 in 2023, reflecting a decrease of 6.1%[18]. - The company's materials cost for the year was HKD 57,652,000, a decrease from HKD 97,659,000 in 2023[29]. - The impairment loss on inventory for 2024 was HKD 544,000, significantly lower than HKD 14,517,000 in 2023, indicating improved inventory management[26]. - The company reported a significant reduction in unallocated expenses, decreasing from HKD 31,306,000 in 2023 to HKD 24,827,000 in 2024[17]. Assets and Liabilities - Current liabilities exceeded current assets by HKD 383,930,000, indicating significant liquidity concerns[8]. - The company's total liabilities amounted to HKD 40,642,000, raising doubts about its ability to continue as a going concern[8]. - The company reported a decrease in non-current assets from HKD 444,856,000 in 2023 to HKD 376,266,000 in 2024, a decline of approximately 15.4%[5]. - The company's cash and cash equivalents decreased from HKD 34,493,000 in 2023 to HKD 16,317,000 in 2024, a drop of about 52.8%[5]. - The debt-to-asset ratio increased to approximately 113% as of December 31, 2024, compared to 94% in 2023, primarily due to net losses incurred by the company[81]. Strategic Initiatives - The company plans to focus on new product development and market expansion strategies to enhance future growth prospects[2]. - The company aims to expand the sales market for its products in mainland China to improve liquidity and profitability[8]. - The company is actively seeking additional financing sources to enhance operational cash flow and meet financial needs[8]. - The company is developing new products such as artificial fish, shrimp, and plant-based milk, and is expanding its market and customer base due to increasing health awareness[80]. - The company anticipates that the strategic financial planning consultant will leverage investment banking relationships to identify potential investors and projects, enhancing growth opportunities[62]. Segment Performance - The group has four reportable segments, each independently managed to assess performance and allocate resources[13]. - The segments include QR code business, packaging products, financial investment, and production and sale of microalgae products[15]. - The total segment loss for 2024 is HKD 43,721,000, significantly improved from a loss of HKD 230,384,000 in 2023[17]. - The financial investment business reported a net income of HKD 4,565,000 in 2024, compared to a loss of HKD 894,000 in 2023[17]. - The revenue from the provision of two-dimensional code packaging products decreased from HKD 13,620,000 in 2023 to HKD 6,328,000 in 2024, a decline of approximately 53.6%[22]. Governance and Compliance - The consolidated financial statements are prepared based on the Hong Kong Financial Reporting Standards and comply with the relevant disclosure requirements[10]. - The company is committed to ensuring the accuracy of its financial reporting and compliance with applicable regulations[10]. - The group has complied with all applicable corporate governance codes as of December 31, 2024[104]. - The independent auditor's report was commissioned to review the consolidated financial statements of the group for the year ending December 31, 2024[68]. - The board of directors includes both executive and non-executive members, ensuring a diverse governance structure[112].
透云生物(01332) - 2024 - 中期财报
2024-09-26 09:43
Financial Performance - For the six months ended June 30, 2024, the company reported a loss attributable to shareholders of HKD 48 million, a decrease of 42.9% compared to a loss of HKD 84 million for the same period in 2023[4] - Revenue for the same period was approximately HKD 74.3 million, down 28.1% from HKD 103.4 million in the prior year, with an overall gross margin of 43.7%, up from 34.4%[4] - The company reported a net loss of approximately HKD 48,819,000 for the six months ended June 30, 2024[51] - The group’s operating loss before tax for the six months ended June 30, 2024, was HKD 49,145,000, an improvement from a loss of HKD 85,081,000 in the previous year[61] - For the six months ended June 30, 2024, the group reported a pre-tax loss of HKD 45,169,000, a decrease from a loss of HKD 55,377,000 in the same period of 2023, indicating an improvement of approximately 18.5%[70] Revenue Breakdown - The QR code business generated revenue of HKD 26 million, with a segment loss of HKD 13.2 million, slightly down from HKD 26.5 million in revenue and a loss of HKD 15 million in the previous year[4] - The packaging products business recorded revenue of HKD 41.5 million, a decrease of 32.0% from HKD 61 million, resulting in a segment loss of HKD 2.7 million compared to a profit of HKD 1.3 million in the prior year[5] - Revenue from sales of goods and services was HKD 73,047,000, with a cost of sales of HKD 41,108,000, resulting in a gross profit of HKD 31,939,000[38] - Revenue from the production and sale of packaging products and provision of QR code packaging solutions was HKD 41,494,000, down from HKD 61,033,000 in the previous year, representing a decline of 32.1%[63] - The QR code solution segment generated revenue of HKD 20,849,000, an increase of 21.6% from HKD 17,179,000 in the prior year[63] - The revenue from the production and sale of Rhine algae products was HKD 5,528,000, significantly down from HKD 16,808,000, marking a decrease of 67.1%[65] - The financial investment segment reported revenue of HKD 1,220,000, compared to a loss of HKD 978,000 in the same period last year[65] Cash Flow and Liquidity - The company held cash reserves of approximately HKD 13.8 million as of June 30, 2024, down from HKD 34.5 million at the end of 2023[9] - Cash flow from operating activities showed a net outflow of HKD 35,566,000, compared to a net inflow of HKD 13,245,000 in the same period last year[48] - Cash and cash equivalents decreased by HKD 20,955,000 during the period, ending with HKD 13,757,000 as of June 30, 2024[48] - The company plans to seek new financing to repay existing loans and improve liquidity, with a total of HKD 118,595,000 owed to certain directors and shareholders[51] - The company is actively exploring the sales market for its products in mainland China to enhance liquidity and profitability[51] Assets and Liabilities - The company’s total assets decreased to HKD 571,843,000 as of June 30, 2024, down from HKD 607,340,000 as of December 31, 2023[42] - Current liabilities increased to HKD 464,754,000 from HKD 380,713,000, resulting in a net current liability of HKD 307,102,000[42] - The company's current liabilities and net liabilities were approximately HKD 307,102,000 and HKD 25,574,000, respectively, as of June 30, 2024[51] - The group’s total bank and other borrowings amounted to HKD 369,187,000 as of June 30, 2024, an increase from HKD 356,344,000 as of December 31, 2023, representing a growth of about 3.6%[91] Shareholder Information - As of June 30, 2024, the company’s directors and senior executives hold a total of 767,500,000 shares, representing approximately 27.35% of the issued shares[20] - The company has a total of 81,806,000 stock options that could potentially be issued, equivalent to about 2.92% of the total issued shares as of the report date[21] - The total number of issued and fully paid shares remained at 2,805,952,000 as of both June 30, 2024, and December 31, 2023[96] - The weighted average number of ordinary shares used to calculate basic and diluted loss per share remained unchanged at 2,805,952,000 shares for both periods[76] Stock Options and Incentives - The company has granted a total of 54,000,000 stock options under the 2012 and 2022 plans, with no options exercisable as of June 30, 2024[101] - The stock options are designed to reward eligible participants contributing to the group's successful operations[100] - The company aims to retain valuable human resources for growth and development through the stock option plans[100] - The total expense recognized for share-based payments for the six months ended June 30, 2024, was HKD 1,620,000, compared to HKD 4,561,000 for the same period in 2023[110] Governance and Compliance - The company has adhered to corporate governance codes throughout the six months ending June 30, 2024, with one non-executive director absent from the annual general meeting[33] - The audit committee reviewed the company's accounting policies and practices for the six months ending June 30, 2024[36] - There were no changes in director information that required disclosure under the listing rules[37] Market Outlook - The company anticipates continued market volatility due to rising interest rates and geopolitical developments, maintaining a cautious strategy[32]
透云生物(01332) - 2024 - 中期业绩
2024-08-23 11:14
Financial Performance - For the six months ended June 30, 2024, the company reported a net loss of HKD 48,819,000, compared to a net loss of HKD 85,103,000 for the same period in 2023, representing a 42.6% improvement in losses[2] - The group reported a net loss of approximately HKD 48,819,000 for the six months ending June 30, 2024[6] - The group reported a loss before tax of HKD 49,145,000 for the six months ended June 30, 2024, compared to a loss of HKD 85,081,000 for the same period in 2023[13] - The group reported a pre-tax loss of HKD 47,969,000 for the six months ended June 30, 2024, compared to a loss of HKD 83,951,000 for the same period in 2023, indicating a reduction in losses by approximately 43%[21] - For the six months ended June 30, 2024, the company recorded a loss attributable to shareholders of HKD 48,000,000, a decrease in loss of 42.9% compared to a loss of HKD 84,000,000 for the same period in 2023[47] Revenue and Profitability - The company's revenue from interest income on lending activities increased significantly to HKD 1,675,000, compared to HKD 296,000 in the previous year, marking a growth of 465.2%[1] - The group's revenue for the six months ended June 30, 2024, was HKD 74,267,000, a decrease of 28.2% compared to HKD 103,367,000 for the same period in 2023[14] - The revenue from the production and sale of packaging products was HKD 41,494,000, down from HKD 61,033,000, representing a decline of 32.1%[14] - The revenue from the production and sale of Laiyin algae products was HKD 5,528,000, down from HKD 16,808,000, indicating a decline of 67.1%[14] - The overall gross profit margin for the group was 43.7%, an increase from 34.4% for the same period in 2023[47] Assets and Liabilities - Total assets as of June 30, 2024, were HKD 414,191,000, down from HKD 444,856,000 at the end of 2023, reflecting a decrease of 6.9%[3] - The company's cash and cash equivalents decreased to HKD 13,757,000 from HKD 34,493,000, a decline of 60.1%[3] - The total liabilities increased to HKD 464,754,000 as of June 30, 2024, compared to HKD 380,713,000 at the end of 2023, representing an increase of 22.1%[3] - The company's non-current liabilities decreased to HKD 132,663,000 from HKD 205,554,000, a reduction of 35.4%[4] - As of June 30, 2024, accounts receivable amounted to HKD 45,763,000, an increase of 16% from HKD 39,356,000 as of December 31, 2023[26] Cost Management and Operational Strategies - The group will implement cost control measures in sales, administrative, and capital expenditures to increase internal cash generation[6] - The group plans to actively seek new financing sources, including additional loans from directors, to address liquidity issues[6] - The board is confident that the financial situation will improve following the implementation of the proposed measures, ensuring sufficient working capital for the next 12 months[7] Shareholder Information - The company did not recommend any interim dividend for the six months ended June 30, 2024, consistent with no dividend declared for the same period in 2023[20] - The average number of ordinary shares used for calculating basic and diluted loss per share remained constant at 2,805,952,000 shares for both periods[21] - The company has a total of 2,805,952,000 shares issued and fully paid as of both December 31, 2023, and June 30, 2024[35] Investments and Financing - Shanghai Tongyun Internet Technology Co., Ltd. agreed to invest RMB 1,500,000 (approximately HKD 1,641,000) to subscribe for 1,500,000 shares of a private equity fund[25] - The company has additional investments in the fund amounting to RMB 4,500,000 (approximately HKD 4,882,000) as of June 30, 2024[63] - The company raised net proceeds of HKD 406,100,000 from share placements, with HKD 263,400,000 used for redeeming convertible notes[65] Taxation - The group reported a tax provision of HKD (326,000) for the six months ended June 30, 2024, compared to HKD 22,000 in 2023, reflecting a significant increase in tax liabilities[19] - The group’s tax rate for qualifying entities in Hong Kong is 8.25% on the first HKD 2,000,000 of profits, and 16.5% on profits exceeding that threshold[18] Market Outlook - The management anticipates a challenging market environment due to rising interest rates and geopolitical developments, emphasizing a cautious strategy[65]
透云生物(01332) - 2023 - 年度财报
2024-04-29 14:35
目錄 2 公司資料 3 主席報告 5 管理層討論及分析 12 董事簡介 15 董事會報告 22 企業管治報告 36 環境、社會及管治報告 76 獨立核數師報告 78 綜合損益及其他全面收益表 80 綜合財務狀況表 82 綜合權益變動表 83 綜合現金流量表 85 綜合財務報表附註 162 五年財務概要 公司資料 董事 執行董事 王亮先生 (主席) 杜東先生 非執行董事 陳輝先生 田宇澤女士 張樂樂先生 賈文杰先生 獨立非執行董事 張榮平先生 夏其才先生 杜成泉先生 胡國華先生 審核委員會 夏其才先生 (主席) 張榮平先生 杜成泉先生 提名委員會 王亮先生 (主席) 杜東先生 張榮平先生 夏其才先生 杜成泉先生 薪酬委員會 杜成泉先生 (主席) 王亮先生 杜東先生 張榮平先生 夏其才先生 授權代表 杜東先生 王亮先生 公司秘書 李安樂女士 註冊辦事處 Clarendon House 2 Church Street Hamilton HM 11 Bermuda 總辦事處及主要營業地點 香港灣仔 杜老誌道6號 群策大廈12樓 獨立核數師 大華馬施雲會計師事務所有限公司 執業會計師 註冊公眾利益實體核數師 主要往來銀 ...
透云生物(01332) - 2023 - 年度业绩
2024-03-28 13:59
Financial Performance - For the fiscal year ending December 31, 2023, the company reported a total loss of HKD 272,569,000, compared to a loss of HKD 202,656,000 in 2022, representing a year-over-year increase in loss of approximately 34.4%[9] - The total comprehensive loss for the year was HKD 271,023,000, compared to HKD 217,395,000 in 2022, reflecting an increase of approximately 24.6%[14] - The group reported a net loss of HKD 272,585 thousand before tax in 2023, compared to a loss of HKD 199,183 thousand in 2022, representing an increase in loss of about 36.8%[50] - The group recorded a loss attributable to shareholders of HKD 268,939,000 for the year ended December 31, 2023, compared to a loss of HKD 198,065,000 in 2022[67] - The loss for the fiscal year was approximately HKD 272.6 million, an increase of about 34.5% from HKD 202.7 million in 2022, primarily due to reduced orders and impairment of property, plant, and equipment[131] Revenue and Sales - The company's revenue from sales of goods and services was HKD 198,032,000, while the cost of sales was HKD 142,036,000, resulting in a gross profit of HKD 55,996,000, down from HKD 127,628,000 in the previous year[7] - The group reported total revenue of HKD 198,032 thousand for 2023, a decrease from HKD 323,334 thousand in 2022, representing a decline of approximately 38.8%[50] - The revenue from the QR code business segment was HKD 70,800 thousand in 2023, down from HKD 99,373 thousand in 2022, reflecting a decrease of about 28.7%[50] - The packaging products business segment generated revenue of HKD 106,909 thousand in 2023, compared to HKD 211,344 thousand in 2022, indicating a decline of approximately 49.5%[50] - The revenue from the China market was HKD 298,949,000 in 2023, down from HKD 370,465,000 in 2022, representing a decline of 19.3%[53] Assets and Liabilities - The company's cash and cash equivalents decreased to HKD 34,493,000 from HKD 128,098,000 in the previous year, indicating a decline of approximately 73%[18] - The company's total liabilities decreased to HKD 380,713,000 from HKD 409,996,000, showing a reduction of about 7.1%[18] - Current liabilities exceeded current assets by HKD 218,229,000, raising significant doubts about the company's ability to continue as a going concern[22] - The net asset value attributable to equity holders decreased significantly to HKD 21,073,000 from HKD 283,509,000[24] - The company recorded a total of HKD 198,640,000 in non-current assets in 2023, a decrease from HKD 315,825,000 in 2022, indicating a decline of 37.1%[53] Operational Strategies and Measures - The company plans to actively seek additional financing sources, including loans from directors, to address liquidity issues[22] - The company aims to expand the sales market for its products in mainland China to improve liquidity and profitability[28] - The company is implementing cost control measures to enhance internal cash generation and operational cash flow[28] - The board believes that the financial situation will improve with the implementation of the above measures, addressing going concern uncertainties[28] - The company’s operational strategies include close monitoring of administrative expenses and operational costs to improve cash flow[129] Financial Investments and Fair Value - The company recorded a net fair value loss on financial assets of HKD 894,000, compared to a loss of HKD 9,899,000 in the previous year, indicating a significant improvement in this area[7] - The financial investment business recorded a fair value loss of approximately HKD 99.5 million, an improvement from HKD 140.3 million in 2022[135] - The group recognized a fair value loss of HKD 1,790,000 upon the sale of all shares in Evergrande Auto, with the total sale amounting to HKD 5,731,000[78] Share Capital and Stock Options - The company’s issued and fully paid share capital remained unchanged at HKD 112,238,000 for both 2022 and 2023[102] - A total of 83,031,000 stock options have been granted and remain unexercised, representing approximately 2.96% of the total shares issued as of the announcement date[107] - The company recognized approximately HKD 2,587,000 in share-based payments for the year ended December 31, 2023, down from HKD 6,859,000 in 2022[117] - The average value per stock option for the year ended December 31, 2023, is estimated between HKD 0.451 and HKD 0.545[117] - The total stock options outstanding as of December 31, 2023, is 47,000,000, with 11,000,000 options canceled[112] Corporate Governance - The company has adhered to the corporate governance code as per the Hong Kong Stock Exchange rules, with one non-executive director absent from the annual general meeting held on June 9, 2023[179] - The board continuously reviews and monitors the company's practices to maintain high standards of corporate governance[180] - All directors confirmed compliance with the trading standards for securities transactions throughout the year[181] Employment and Human Resources - As of December 31, 2023, the group employed approximately 563 full-time employees and 5 part-time employees in Hong Kong and China, a decrease from 570 full-time and 8 part-time employees in 2022[149]
透云生物(01332) - 2023 - 中期财报
2023-09-28 09:29
Financial Performance - The company reported a loss attributable to shareholders of HKD 84 million for the six months ended June 30, 2023, a decrease of 4.7% compared to a loss of HKD 88.1 million for the same period in 2022[5]. - Revenue for the six months ended June 30, 2023, was approximately HKD 103.4 million, a decrease of about 37.8% from HKD 166.3 million in the same period of 2022[5]. - The overall gross profit margin for the company was 34.4% for the six months ended June 30, 2023, compared to 35.1% for the same period in 2022[5]. - The company reported a net loss attributable to the owners of the company was HKD 83,951,000, compared to HKD 88,066,000 in 2022, indicating a reduction of 4.8%[59]. - The total comprehensive loss for the period was HKD 84,178,000, an improvement from HKD 93,932,000 in the same period last year, reflecting a decrease of 10.0%[60]. - The company recorded a loss before tax of HKD 85,081,000, slightly improved from a loss of HKD 86,308,000 in the previous year, representing a decrease of 1.4%[59]. - The company reported a financial cost of HKD 4,162,000, significantly lower than HKD 20,670,000 in the previous year, indicating a decrease of 80.0%[59]. - The group’s other income, gains, and losses for the six months ended June 30, 2023, showed a net loss of HKD 45,091,000, an improvement from a loss of HKD 48,613,000 in the same period of 2022[89]. Revenue Breakdown - The QR code business generated revenue of HKD 26.5 million, a decrease of 30.6% from HKD 38.2 million in the previous year, with a segment loss of HKD 15 million[6]. - The packaging products business recorded revenue of HKD 61 million, down 50.7% from HKD 123.8 million in the previous year, with a segment profit of HKD 1.3 million[7]. - Revenue from packaging products was HKD 61,033,000, down 50.7% from HKD 123,792,000 in the previous year[85]. - Revenue from QR code packaging products and solutions was HKD 26,504,000, a decline of 30.7% from HKD 38,249,000 in 2022[87]. - Revenue from the production and sale of spirulina products increased significantly to HKD 16,808,000, compared to HKD 4,022,000 in the same period last year, representing a growth of 318.5%[87]. - Revenue from the European market for packaging products was HKD 26,505,000, a decrease of 10.3% from HKD 29,549,000 in the previous year[87]. - Revenue from the packaging products business in Hong Kong and China was HKD 25,187,000, down 69.8% from HKD 83,218,000 in 2022[87]. Assets and Liabilities - As of June 30, 2023, the company's total assets less current liabilities amounted to HKD 416,622,000, down from HKD 477,701,000 at the end of 2022[64]. - The company's cash and cash equivalents decreased significantly to HKD 40,145,000 from HKD 128,098,000 at the end of 2022, a decline of 68.7%[63]. - Non-current liabilities increased to HKD 212,730,000 from HKD 194,192,000, representing a rise of 9.6%[64]. - The company's equity attributable to owners decreased to HKD 185,494,000 from HKD 263,959,000, a decline of 29.7%[64]. - The company has a current liability exceeding current assets by approximately HKD 154,878,000, raising concerns about its ability to continue as a going concern[70]. - Trade receivables decreased from HKD 51,348,000 on December 31, 2022, to HKD 41,528,000 on June 30, 2023, with a provision for impairment of HKD 10,260,000[102]. - The group’s non-collateralized loans and interest receivables dropped from HKD 64,020,000 on December 31, 2022, to HKD 35,272,000 on June 30, 2023[105]. - Trade payables decreased from HKD 46,224,000 on December 31, 2022, to HKD 26,314,000 on June 30, 2023[108]. - Other payables and accrued liabilities totaled HKD 27,503,000 as of June 30, 2023, down from HKD 35,098,000 at the end of 2022[110]. - The group’s secured bank borrowings were HKD 59,645,000 as of June 30, 2023, compared to HKD 79,258,000 on December 31, 2022[111]. - The total amount of bank and other borrowings was HKD 380,113,000 on June 30, 2023, down from HKD 347,275,000 at the end of 2022[113]. Investments - The company reported a fair value loss of HKD 47.8 million on financial assets measured at fair value through profit or loss, compared to a loss of HKD 50.8 million in the same period last year[8]. - As of June 30, 2023, the group held listed investments valued at approximately HKD 6,200,000, unlisted investments at HKD 185,300,000, and private equity fund investments at HKD 6,500,000[36]. - The total fair value of investments as of June 30, 2023, was HKD 185,293,000, reflecting a decrease of HKD 48,272,000 compared to the previous period[38]. - The investment in China Evergrande New Energy Vehicle Group Limited amounted to 5,000,000 shares, with a fair value of HKD 6,200,000 and an unrealized loss of HKD 32,297,380[38]. - The group plans to continue monitoring its investment portfolio cautiously due to external economic challenges, including bank failures and debt default risks[50]. - The group’s investment in FreeOpt Holdings Limited showed a fair value decrease of HKD 24,483,000, with a total investment cost of HKD 150,000[36]. - The group’s investment in Seekers Partners Limited resulted in an unrealized loss of HKD 498,639, with a total investment cost of HKD 53,217[36]. - The group’s investment in Triton Algae Innovations, Ltd showed a fair value increase of HKD 8, with a total investment cost of HKD 27,300[36]. Employee and Management - As of June 30, 2023, the group had approximately 569 full-time employees in Hong Kong and mainland China, down from 570 full-time employees as of December 31, 2022[19]. - The total employee benefits expense decreased to HKD 55,377,000 in the first half of 2023, compared to HKD 65,014,000 in the same period of 2022[91]. - The company’s management team and employees were acknowledged for their professionalism and contributions to the group[22]. Shareholder and Dividends - The board did not recommend any interim dividend for the six months ended June 30, 2023, consistent with the previous year[20]. - The company reported that Mr. Wang Liang holds 622,500,000 shares, representing approximately 22.18% of the company's issued shares as of June 30, 2023[24]. - The company has commitments from directors and shareholders not to demand repayment of HKD 105,448,000 until there is sufficient cash available[71]. Stock Options and Share-Based Payments - The company has a total of 138,352,250 stock options granted under the 2012 plan, of which 78,135,577 are immediately exercisable, representing approximately 2.78% of the total issued shares as of June 30, 2023[120]. - The company recognized an expense of HKD 4,561,000 for share-based payments for the six months ended June 30, 2023, compared to HKD 8,855,000 for the same period in 2022[131]. - The stock options granted on February 21, 2019, have an exercise price of 0.48 HKD and a total of 30,000,000 options are available for other participants[124]. - The stock options granted on October 8, 2020, have an exercise price of 0.40 HKD, with a total of 36,000,000 options available for exercise[126]. - The company aims to reward and incentivize qualified participants contributing to its successful operations through the stock option plans[117]. Financial Instruments and Fair Value - The fair value of financial assets and liabilities measured at cost or amortized cost does not differ significantly from their fair value as of June 30, 2023[134]. - The total fair value of financial assets measured at fair value through profit or loss decreased from HKD 186,086,000 on December 31, 2022, to HKD 155,293,000 on June 30, 2023, reflecting a loss of HKD 30,793,000[149]. - The company experienced a net loss of HKD 140,372,000 in fair value adjustments for non-listed equity instruments during the reporting period[149]. - The fair value measurement for financial instruments did not involve any transfers between Level 1 and Level 2 inputs during the first half of 2023[143]. - The fair value of non-listed equity investments was primarily determined by the company's directors as of June 30, 2023[149].